Biological subtype, treatment response and outcomes in inflammatory breast cancer using data from the National Cancer Database

2020 ◽  
Vol 107 (8) ◽  
pp. 1033-1041 ◽  
Author(s):  
A. R. Kupstas ◽  
T. L. Hoskin ◽  
C. N. Day ◽  
J. C. Boughey ◽  
E. B. Habermann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Treatment Response ◽  
Inflammatory Breast Cancer ◽  
National Cancer Database ◽  
Using Data ◽  
Biological Subtype

scholarly journals Inflammatory Breast Cancer: Clinical Characteristics and Influence of Molecular Subtypes on Treatment Response

2021 ◽  
Vol 107 (1_suppl) ◽  
pp. 12-12
Author(s):  
D Aissaoui ◽  
M Bohli ◽  
R Ben Amor ◽  
J Yahyaoui ◽  
A Hamdoun ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Treatment Response ◽  
Inflammatory Breast Cancer ◽  
Hormone Receptor ◽  
Triple Negative ◽  
Molecular Subtypes ◽  
Luminal A ◽  
Her2 Positive ◽  
Luminal B ◽  
Significant Difference

Introduction: Inflammatory Breast Cancer (IBC) is a rare and very aggressive breast cancer with poor prognosis. The prevalence is different from a country to another. In Tunisia, it is about 5 to 7% of breast cancer. The aim of this study is to describe the epidemiological and histopathological features of patients with inflammatory breast cancer and to evaluate the treatment response according to the molecular subtypes. Methods: This retrospective review identified 31 patients with no metastatic IBC treated in our radiotherapy department between December 2019 and November 2020. IBC was confirmed using the clinical criteria. Baseline clinic-pathological and treatment information was retrieved from medical records. Statistical analysis was performed with IBM SPSS V.20. Results: Median age was 51.3 years [27-68]. 48% of tumors were grade 3. The average tumor size was 36mm [10-90]. The histological type was ductal carcinoma in 97%. Vascular invasion was noted in 24 patients (77%). Thirty patients were classified as stage IIIB and one patient was IIIC. 74% were hormone receptor positive and 45% were HER2 positive. Luminal B was the predominant subtype (52%) followed by Her2 positive (32%), Luminal A (23%), and triple negative (3%) All patients had chemotherapy: neoadjuvant for 26 patients (84%) and adjuvant for 5 patients (16%). Nine patients (29%) had tumor pathological complete response (pCR). Partial response was observed in 18 patients (58%). Lymph node pCR was noted in 16% of cases (n=5). Endocrine therapy and trastuzumab were given to 76% and 45% of patients, respectively. The influence of the molecular subtype was not statistically significant on the response to neoadjuvant treatment. The highest rate of pCR were 43% for Her2positive, then 27%, 21% and 9% for Luminal B, Luminal A and Triple negative, respectively (p=0.2). Conclusion: Our study showed a high percentage of hormone receptor and Her2+ (74% and 45% respectively) in IBC. Luminal B was the most frequent subtype. Anthracycline-based chemotherapy and trastuzumab improved the pCR rate: 44% for Her2positive. Triple negative showed poorer pCR than other breast cancer subtype without a significant difference. A larger study is warranted to confirm our findings.

scholarly journals Pathologic Complete Response (pCR) and Survival of Women with Inflammatory Breast Cancer (IBC): An Analysis Based on Biologic Subtypes and Demographic Characteristics

2019 ◽  
Vol 16 (1) ◽  
pp. 124 ◽  
Author(s):  
Tithi Biswas ◽  
Charulata Jindal ◽  
Timothy L. Fitzgerald ◽  
Jimmy T. Efird
Keyword(s):  
Breast Cancer ◽  
Inflammatory Breast Cancer ◽  
Private Health Insurance ◽  
Triple Negative ◽  
Pathologic Complete Response ◽  
Multivariable Analysis ◽  
Complete Response ◽  
National Cancer Database ◽  
Tumor Patient ◽  
Poorly Differentiated

In this US-based study of the National Cancer Database (NCDB), we examined 8550 patients diagnosed with non-metastatic, invasive inflammatory breast cancer (IBC) who received surgery from 2004–2013. Patients were grouped into four biologic subtypes (HR+/HER2−, HR+/HER2+, HR−/HER2+, HR−/HER2−). On average, women were 56 years of age at diagnosis and were followed for a median of 3.7 years. The majority were white (80%), had private health insurance (50%), and presented with poorly differentiated tumors (57%). Approximately 46% of the cancers were >5 cm. Most patients underwent mastectomy (94%) and received radiotherapy (71%). Differences by biologic subtypes were observed for grade, lymph node invasion, race, and tumor size (p < 0.0001). Patients experiencing pathologic complete response (pCR, 12%) vs. non-pCR had superior 5-year overall survival (OS) (77% vs. 54%) (p < 0.0001). Survival was poor for triple-negative (TN) tumors (37%) vs. other biologic subtypes (60%) (p < 0.0001). On multivariable analysis, TN-IBC, positive margins, and not receiving either chemotherapy, hormonal therapy or radiotherapy were independently associated with poor 5-year survival (p < 0.0001). In this analysis of IBC, categorized by biologic subtypes, we observed significant differential tumor, patient and treatment characteristics, and OS.

scholarly journals Pathologic Complete Response (pCR) and Survival of Women with Inflammatory Breast Cancer (IBC): An Analysis Based on Biologic Subtypes and Demographic Characteristics

2018 ◽  
Author(s):  
Tithi Biswas ◽  
Charulata Jindal ◽  
Timothy Fitzgerald ◽  
Jimmy Efird
Keyword(s):  
Breast Cancer ◽  
Inflammatory Breast Cancer ◽  
Private Health Insurance ◽  
Triple Negative ◽  
Pathologic Complete Response ◽  
Multivariable Analysis ◽  
Complete Response ◽  
National Cancer Database ◽  
Tumor Patient ◽  
Poorly Differentiated

The aim of this study was to examine pathologic complete response (pCR) and overall survival (OS) of patients diagnosed with non-metastatic inflammatory breast cancer (IBC). A total of N=8,550 cases undergoing surgery were identified between 2004-2013, using the National Cancer Database (NCDB). Patients were grouped into 4 biologic subtypes (HR+/HER2-, HR+/HER2+, HR-/HER2+, HR-/HER2-). The median age at diagnosis was 56 years. On average, women were followed for 3.7 years [interquartile range=3.0]. The majority were white (80%), had private health insurance (50%), and presented with poorly differentiated tumors (57%). Approximately 46% of the cancers were &gt;5cm. Most patients underwent mastectomy (94%) and received radiotherapy (71%). Differences by biologic subtypes were observed for grade, lymph node invasion, race, and tumor size (p&lt;.0001). Compared with non-pCR (54%), patients experiencing pCR had superior 5-year survival (77%) (p&lt;.0001). Survival was poor for triple-negative (TN) tumors (37%) vs. other biologic subtypes (60%) (p&lt;.0001). On multivariable analysis, TN-IBC, positive margins, and not receiving either chemotherapy, hormonal therapy or radiotherapy were independently associated with poor 5-year survival (p&lt;.0001). In this large multicentric analysis of IBC, categorized by biologic subtypes, we observed significant differential tumor, patient and treatment characteristics, and OS.

scholarly journals Breast Reconstruction in Inflammatory Breast Cancer: An Analysis of Predictors, Trends, and Survival from the National Cancer Database

2021 ◽  
Vol 9 (4) ◽  
pp. e3528
Author(s):  
Murad J. Karadsheh ◽  
Jacob Y. Katsnelson ◽  
Karen J. Ruth ◽  
Eric S. Weiss ◽  
James C. Krupp ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Reconstruction ◽  
Inflammatory Breast Cancer ◽  
National Cancer Database

scholarly journals Breast Reconstruction in Inflammatory Breast Cancer: An Analysis of Predictors, Trends, and Survival from the National Cancer Database

2020 ◽  
Vol 8 (9S) ◽  
pp. 22-23
Author(s):  
Murad J. Karadsheh ◽  
Jacob Katsnelson ◽  
Eric S. Weiss ◽  
James C. Krupp ◽  
Elin R. Sigurdson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Reconstruction ◽  
Inflammatory Breast Cancer ◽  
National Cancer Database

Inflammatory Breast Cancer: Correlation between Clinical and Radiologic Findings

1997 ◽  
Vol 37 (4) ◽  
pp. 763
Author(s):  
Hye Won Lee ◽  
Jeong Mi Park ◽  
Sei Hyun Ahn ◽  
Gyungyup Gong
Keyword(s):  
Breast Cancer ◽  
Inflammatory Breast Cancer ◽  
Radiologic Findings

INFLAMMATORY BREAST CANCER FOLLOWED BY CONTRALATERAL BREAST METASTASIS WITH INFLAMMATORY CHANGE

1995 ◽  
Vol 45 (5) ◽  
pp. 413-418
Author(s):  
TATSUMASA ANDOH ◽  
YUICHI IINO ◽  
HIDETADA AOYAGI ◽  
NORITAKA SUGAMATA ◽  
HIROYUKI TAKEI ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Inflammatory Breast Cancer ◽  
Contralateral Breast ◽  
Inflammatory Change ◽  
Breast Metastasis
Sign in / Sign up

Export Citation Format

Share Document